diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ff0765e39..096f34c29 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics. + +### Additional Evidence (extend) +*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* + +WHO issued conditional recommendations (not full endorsements) for GLP-1s, acknowledging 'limited long-term evidence' and requiring countries to consider 'local cost-effectiveness, budget impact, and ethical implications.' The conditional framing and emphasis on budget impact analysis suggests WHO recognizes the chronic use cost challenge, particularly for low/middle-income countries where affordability is a barrier to sustained treatment. + --- Relevant Notes: diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index eae369d26..aa2465796 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes. + +### Additional Evidence (confirm) +*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* + +WHO's three-pillar framework for GLP-1 treatment explicitly positions medication as one component within a comprehensive approach including healthy diets, physical activity, professional support, and population-level policies. WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical interventions alone cannot address health outcomes driven by behavioral and social factors. + --- Relevant Notes: diff --git a/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md b/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md index c3c731b66..9fafa8b20 100644 --- a/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md +++ b/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md @@ -7,9 +7,13 @@ date: 2025-12-01 domain: health secondary_domains: [] format: policy -status: unprocessed +status: enrichment priority: medium tags: [glp-1, WHO, global-health, obesity, guidelines, equity] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -39,3 +43,10 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic + + +## Key Facts +- WHO issued conditional (not full) recommendations for GLP-1 medicines in obesity treatment in December 2025 +- WHO framework has three pillars: population-level policies, high-risk protection, and person-centered care +- WHO guideline emphasizes GLP-1s must be combined with healthy diets, physical activity, and professional support +- WHO requires countries to assess local cost-effectiveness and budget impact before adoption